SCHEMBL2608239

SCHEMBL2608239

C=C(C)C(=O)NCCCCOC(C)C

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
EPHX2 P34913 1/20 0.39
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2608244 0.98 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1
SCHEMBL1197607 0.95 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1
SCHEMBL553153 0.87 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1
SCHEMBL167252 0.84 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1
SCHEMBL4849807 0.83 KMT2A (0.49) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1
SCHEMBL23175608 0.82 KDM4E (0.58) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1
SCHEMBL24495946 0.82 CYP2C19 (0.42) KMT2AEPHX2KDM4E
SCHEMBL2608199 0.81 ACHE (0.39) ALDH1A1TSHRKDM4E
SCHEMBL907569 0.81 KDM4E (0.52) ALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL23420002 0.80 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HTTTSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345180-B2 Display medium for assessment and method for manufacturing same ZEON CORPORATION (JP) 2022-05-31 US disclosed
US-20190184732-A1 DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME ZEON CORPORATION (JP) 2019-06-20 US disclosed
US-8158021-B2 Polymerizable liquid crystal compound, polymerizable liquid crystal composition, liquid crystalline polymer, and optical anisotropic article ZEON CORPORATION (JP) 2012-04-17 US disclosed
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE ZEON CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE LEO1, ZYX, CCNT1 ALDH1A1 2720/4885SMN1; SMN2 4179/4885HTT 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.